The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Celgene; Merck Serono; Roche
Consulting or Advisory Role - Bayer; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche
 
Junji Furuse
Honoraria - Ajinomoto; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Meiji Seika Kaisha; Merck Serono; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sawai Pharmaceutical Co; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical; Zeria Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hisamitsu Pharmaceutical (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Kayaku (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck; Merck Serono; Millennium; Novartis; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical
 
Volker Heinemann
Honoraria - Amgen; Celgene; Merck; Roche; Sanofi; Sirtex Medical
Consulting or Advisory Role - Amgen; Baxalta; Boehringer Ingelheim; Celgene; Merck; Roche; Sanofi; Sirtex Medical
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Sirtex Medical (Inst)
Travel, Accommodations, Expenses - Amgen; Merck; Roche; Sirtex Medical
 
Tatsuya Ioka
Consulting or Advisory Role - Chugai Pharma; Taiho Pharmaceutical; Yakult Honsha
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Eisai; Janssen; Lilly; Mochida Pharmaceutical Co. Ltd.; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); Nihon Zouki (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Merck Serono; Novartis
 
Igor Bazin
Consulting or Advisory Role - Bayer
 
Makoto Ueno
Honoraria - Abbott Japan; AstraZeneca; Boston Scientific; Kyowa Hakko Kirin; Lilly; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Zeria Pharmaceutical
 
Tibor Csõszi
No Relationships to Disclose
 
Harpreet Wasan
Honoraria - Merck KGaA
Speakers' Bureau - Merck KGaA
Research Funding - Merck KGaA (Inst)
Travel, Accommodations, Expenses - Merck KGaA
 
Bohuslav Melichar
Honoraria - Merck; Roche/Genentech
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Merck; Roche
 
Petr Karasek
No Relationships to Disclose
 
Teresa Macarulla
No Relationships to Disclose
 
Carmen Guillén Ponce
Consulting or Advisory Role - Bayer; Celgene; Merck Serono; Roche; Sanofi
 
Ewa Kalinka-Warzocha
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis
 
Zsolt Horvath
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer; Roche
 
Hans Prenen
No Relationships to Disclose
 
Michael Schlichting
Employment - Merck KGaA
 
Fazal Mehdi
Employment - EMD Serono
 
Johanna C. Bendell
No Relationships to Disclose